Intercell announces new management structure Thomas Lingelbach appointed new CEO
New Supervisory Board members proposed
Intercell AG announced that the company’s Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011.
At the same time, Gerd Zettlmeissl, current CEO, will resign to pursue other personal and professional interests. Under his leadership, Intercell received international approval for the novel Japanese Encephalitis vaccine, IXIARO®/JESPECT®, formed major strategic alliances with leading pharmaceutical companies and vaccine non‐profit organizations, successfully completed several financing steps, was elected as ‘Technology Pioneer’ at the World Economic Forum in 2009 and received the European Biotechnica Award in 2006.
The company will propose to the next General Assembly the election of two new members of the Supervisory Board, Alexander von Gabain, and Thomas Szucs, both of whom have extended experience in the field of vaccines and pharmaceutical development. One current member of the Supervisory Board, David Ebsworth, intends to resign due to the demands on his time required by recent increased executive responsibilities he is taking on in Switzerland as CEO of Galenica AG.
Thomas Lingelbach has more than twenty years of experience in the pharma and vaccines industry, having held a variety of leading positions of increasing international responsibility at Hoechst AG, Chiron Vaccines, and Novartis Vaccines and Diagnostics, before joining Intercell in 2006 as Chief Operating Officer. His experience ranges broadly and deeply in the areas of Industrial Operations, Product Development, and Commercial Operations. At Intercell, Thomas Lingelbach has been inter alia chiefly responsible for the manufacturing and March 2009 licensure in the U.S. and Europe of the company’s first product, a vaccine to prevent Japanese Encephalitis.
Other news from the department people
